Health utility scores (HUS), a form of health-related quality of life (HRQoL) assessments useful in economic analyses, such as the EuroQol (EQ-5D) were originally standardized to health state preferences in healthy individuals. To demonstrate clinical appropriateness in cancer patients, we assessed the association of common cancer symptoms with EQ-5D HUS.
Adult cancer outpatients were surveyed cross-sectionally using the Edmonton Symptom Assessment System (ESAS), the EQ-5D-3L, and clinico-demographic variables. ESAS rated symptoms from 0-10. HUS were derived from the EQ-5D-3L (Canadian conversion). ESAS symptoms were correlated with HUS using Spearman correlation coefficients (R). Multivariable regression analyses identified independent variables associated with HUS.
Of 764 patients across multiple cancers, 27% were palliative at assessment. There were significant correlations between each ESAS symptom score and HUS (p
HUS is associated with many cancer symptoms, including pain, fatigue, nausea, depression, anxiety, drowsiness, loss of appetite, and shortness of breath. EQ-5D-3L derived HUS have clinical utility. On exploratory analysis, we cannot replace accurately the EQ5D with ESAS, although we can replace two symptom questions within EQ5D with ESAS with high correlation.
Clinical trial identification
Legal entity responsible for the study
Princess Margaret Cancer Centre, UHN, Toronto, Canada
Cancer Care Ontario
All authors have declared no conflicts of interest.